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Abstract
There is growing evidence that activated synovial fibroblasts, as part of a complex cellular
network, play an important role in the pathogenesis of rheumatoid arthritis. In recent years,
significant progress has been made in elucidating the specific features of these fibroblasts.
It has been understood that although macrophage and lymphocyte secreted factors
contribute to their activation, rheumatoid arthritis synovial fibroblasts (RA-SFs) do not
merely respond to stimulation by pro-inflammatory cytokines, but show a complex pattern of
molecular changes also maintained in the absence of external stimulation. This pattern of
activation is characterized by alterations in the expression of regulatory genes and signaling
cascades, as well as changes in pathways leading to apoptosis. These together result in
the upregulation of adhesion molecules that mediate the attachment of RA-SFs to the
extracellular matrix and in the overexpression of matrix degrading enzymes that mediate the
progressive destruction of the joints. In addition, activated RA-SFs exert specific effects on
other cell types such as macrophages and lymphocytes. While the initiating step in the
activation of RA-SFs remains elusive, several key pathways of RA-SF activation have been
identified. However, there is so far no single, specific marker for this phenotype of RA-SF. It
appears that activated RA-SFs are characterized by a set of specific properties which
together lead to their aggressive behavior.
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Introduction
Rheumatoid arthritis (RA) is a chronic disorder primarily
affecting the joints and leading to their progressive
destruction. This joint destruction is a unique and most
prominent feature of RA that not only distinguishes the
disease from other arthritic conditions, but also deter-
mines the outcome of RA in most affected individuals [1].
Research in recent years has produced exciting new infor-
mation about the pathogenesis of RA. Apart from the mul-
titude of specific data that have been published by many
investigators, two fundamental concepts have been of par-
ticular importance. First, it has been understood that the
pathogenesis of RA is characterized by the concerted
action of different cell types that, through highly specific
communication, create the great variety of signs and
symptoms characteristic of RA. Based on this awareness,
the initial view of active players and passive responders
has been replaced largely by that of several cell types
being involved actively in the pathogenesis of disease
[2,3]. Second, it has become clear that inflammation andArthritis Research    Vol 2 No 5 Pap et al
auto-immunity are key features of RA, but do not consti-
tute by far the only relevant mechanisms of disease.
Instead, growing evidence suggests that, in addition to
macrophages and T cells, activated synovial fibroblasts
(SFs) play a major role in both initiating and driving RA [4].
Therefore, these cells have been studied intensively over
recent years, and it has been understood that the specific
properties of activated RA-SFs not only cause their
aggressive behavior, but may also explain some other
aspects of RA. By focusing on recent data, this review will
outline the current knowledge about the molecular
changes in activated RA-SFs and point to the conse-
quences with respect to the pathogenesis of disease.
Morphology and altered behavior of activated
RA-SFs
A key observation concerning SFs in RA was the descrip-
tion of different subpopulations within the synovial mem-
brane [5]. It is now well established that RA-SFs in the
most superficial layer of the synovium—the lining—differ sub-
stantially not only from SFs in normal synovial tissue, but
also from SFs in deeper layers of the rheumatoid synovium.
These differences appear characteristic for RA and can be
seen both in the morphology and in biological properties.
Specifically, RA-SFs in the lining layer display numerous
features of cellular activation that ultimately result in an
aggressive, invasive behavior. At a morphological level, a
more rounded shape, a large pale nucleus and prominent
nucleoli characterize the activated phenotype of RA-SFs. In
culture, these cells grow in an anchorage-independent
manner [6] over multiple passages and can escape contact
inhibition. The most characteristic feature is the ability of
activated RA-SFs to attach to the articular cartilage and
deeply invade the extracellular matrix. Apart from the ques-
tion of what initiates cellular activation, the problem of
whether the activation of RA-SFs is an intrinsic property of
these cells or is purely a response to inflammatory
cytokines has been of crucial importance. Growing evi-
dence interestingly suggests that the changes resulting in
the activation (sometimes also called partial transformation)
of RA-SFs constitute stable long-term alterations that are
maintained even in the absence of pro-inflammatory
cytokines. The most convincing piece of evidence support-
ing this hypothesis has come from the severe combined
immunodeficient mouse co-implantation model of RA [7]. In
this model, isolated RA-SFs are implanted with normal
human cartilage under the renal capsule of severe com-
bined immunodeficient mice. Because of the lack of a func-
tional immune system, these mice do not reject the
implants, allowing one to study the interaction of the
RA-SFs with the normal articular cartilage. As shown in
several studies, RA-SFs attach to and deeply invade the
co-implanted cartilage in this in vivo model of RA [7–10].
In contrast, normal SFs, osteoarthritis SFs or dermal fibrob-
lasts do not show such an invasive behavior. This experi-
mental setting investigates the invasive behavior of RA-SFs
in the absence of human inflammatory cells and cytokines;
therefore, the differences in the behavior of RA-SFs,
osteoarthritis SFs and normal SFs have been taken as evi-
dence for the stable, intrinsic activation of RA-SFs.
Alterations in signaling pathways and
apoptosis
Several lines of evidence indicate that both the altered
morphology and the aggressive behavior of RA-SFs result
from specific changes in the transcription of disease-
relevant genes and in intracellular signaling cascades.
Among the factors involved in the activation of RA-related
genes, the AP-1 transcription factor is of special interest. It
consists of the c-Fos and c-Jun elements, and is key in sig-
naling pathways that ultimately lead to the degradation of
cartilage and bone. Several studies have shown that c-fos
is overexpressed in the RA synovium [11–14]. Asahara et
al analyzed nuclear extracts from synovial cells and found a
high DNA-binding activity of AP-1 in the tissues of RA
patients, but negligible activity in osteoarthritis tissue speci-
mens [15]. This is important because the promoters of
several disease-relevant genes such as those encoding
matrix metalloproteinases (MMPs) contain binding sites for
AP-1. In addition, the AP-1 transcription factor is involved
in the tissue-specific expression of MMPs [16]. Interest-
ingly, AP-1 activity is found predominantly in fibroblast-like
cells, and correlates with both the in situ expression of
c-fos and c-jun mRNA and disease activity [15].
The transcription factor NF-kB is also activated in RA-SFs
[17], and appears to be important in perpetuating disease
as well as in mediating synovial inflammation [17–20]. Not
only is NF-kB induced by several pro-inflammatory
cytokines, but also its activation conversely stimulates the
transcription of disease-relevant genes such as those
encoding adhesion molecules and cytokines. Conse-
quently, overexpression of IkBa, the natural inhibitor of
NF-kB, leads to the downregulation of pro-inflammatory
cytokines. In addition, recent data have linked NF-kB with
reduced apoptosis of synovial cells [17]. Like AP-1, NF-kB
induces the expression of MMPs [21], but it is unclear
which regulatory pathway contributes most significantly to
the altered expression of MMPs in RA.
Tumor suppressor genes have recently become of interest
in explaining important features of cellular activation of
RA-SFs. Thus, alterations in the expression and function of
p53 have been associated with some important features
of RA-SFs because Firestein et al described somatic
mutations of p53 in RA-SFs [22]. The predicted amino
acid substitutions, interestingly, are similar to those com-
monly observed in a variety of tumors. It was concluded
from these data that, by resulting in a nonfunctional ‘cell
death suppressor’, such mutations could contribute to an
extended life span of activated cells aggressively destroy-
ing cartilage and bone. Further evidence supporting thishttp://arthritis-research.com/content/2/5/361
hypothesis has emerged from recent observations demon-
strating that the inhibition of p53 causes the transforma-
tion of normal SFs into cells with aggressive behavior
characteristic of that seen in RA [23]. As shown in a study
by Kullmann et al, RA patients from another part of the
world did not reveal mutations of p53 [24]; therefore, it
may be hypothesized that inhibition of p53 constitutes
only part of the mechanism of cellular activation in RA, and
that the pattern of cellular changes differs within the
affected patients.
Our laboratory recently demonstrated that aggressive
RA-SFs lack the expression of mRNA for the novel tumor
suppressor  PTEN  [10], the protein product of which
exhibits tyrosine phosphatase activity as well as extensive
homology to the cytoskeletal proteins tensin and auxillin
[25]. In situ hybridization on a RA synovium revealed a dis-
tinct expression pattern of PTEN, with negligible staining
in the lining layer but abundant expression in the sublining.
In contrast, normal synovial tissue exhibited homogeneous
staining for PTEN [10]. Only 40% of cultured RA-SFs
expressed PTEN, and severe combined immunodeficient
mouse experiments showed no staining for PTEN in those
cells aggressively invading the cartilage. A recent study of
interest by Di Cristofano et al demonstrated that PTEN is
involved critically not only in the aggressive behavior of
cells, but also as an essential mediator of Fas response
[26], providing a further link between invasiveness and
resistance to apoptosis in activated cells.
The question of whether the massive synovial hyperplasia
characteristic for RA is mainly due to the proliferation of
RA-SFs or to defective apoptosis is still a matter for dis-
cussion. Over recent years, evidence has been accumu-
lated for both hypotheses. On the basis of the well-known
phenomenon that RA-SFs can grow very fast over multiple
passages in vitro, cell proliferation has been considered
the major mechanism for the hyperplastic growth of the
RA synovium. Support for this notion has come from the
demonstration that key regulators of cellular proliferation,
such as the proto-oncogene c-myc, are overexpressed in
RA [27]. In addition, recent data from Hashiramoto et al
and from our own laboratory indicate that inhibition of
c-myc through gene transfer reduces the growth of
RA-SFs [9,28]. In the context of synovial cell proliferation,
interesting data have arisen from a study by Taniguchi et
al [29], which show that gene transfer with the p16INK4a
senescence gene only inhibited the growth of SFs in vitro,
but ameliorated the course of rat adjuvant arthritis as well
when applied in vivo [29].
The hypothesis that proliferation of activated RA-SFs con-
stitutes the major driving force of synovial hyperplasia has
been challenged by observations indicating SFs do not
proliferate faster than cells from osteoarthritis patients [30].
Studies using 3H-thymidine incorporation revealed a
proliferation rate of only 1–5% [31], and mitosis is also
rarely found in RA synovial tissue [32]. There is accumulat-
ing evidence that an alteration in apoptosis contributes sig-
nificantly to the synovial hyperplasia in RA. Despite earlier
reports, based on results from experiments using DNA
labeling techniques, suggesting an increased rate of apop-
tosis among RA-SFs [33], recent data have demonstrated
that apoptosis is a rare event in the rheumatoid synovium
[34]. The lack of apoptosis in RA-SFs appears to have two
aspects: the missing ability of RA-SFs to complete path-
ways initiated by pro-apoptotic stimuli, and the partial resis-
tance to such stimuli. The former is documented by the
aforementioned discrepancy between the high number of
DNA strand breaks and the low frequency of completed
apoptosis. The resistance of RA-SFs to apoptosis is
caused by the prominent upregulation of anti-apoptotic
molecules in RA-SFs. In this context, the induction of apop-
tosis through the Fas/Apo-1/CD95 pathway is of particular
interest [35]. Several reports have demonstrated that
RA-SFs are susceptible to Fas-induced apoptosis [35].
This appears to apply only to about 20% of RA-SFs
however; the majority are not only unable to complete
apoptosis, but are also resistant to the induction of apopto-
sis through the Fas pathway. Recent data indicate that this
specific feature of RA-SFs is linked to the expression of
several anti-apoptotic molecules that counteract key path-
ways in the apoptosis cascade. In this context, we have
demonstrated most recently the overexpression of sentrin
in RA-SFs [36]. Sentrin (also called SUMO-1) is a ubiqui-
tin-like protein that has been shown to interact with the
signal-competent forms of Fas/Apo-1 and tumor necrosis
factor (TNF) receptor-1, and thereby to protect cells
against apoptosis mediated by Fas and TNF [37]. Sentrin
is, interestingly, found predominantly in RA-SFs of the lining
layer. In contrast, normal synovial cells express very little
sentrin [36]. Quantitative analysis of sentrin expression in
cultured SFs revealed an increase of sentrin mRNA expres-
sion of greater than 30-fold as compared with osteoarthritis
SFs and normal fibroblasts [36]. Taken together, alteration
in the ability to undergo apoptosis may not only play a role
in the hyperplasia of the rheumatoid synovium, but also,
even more importantly, extend the life span of activated
RA-SFs at sites of matrix degradation, thus contributing
indirectly to the destruction of articular structures.
Adhesion molecules
One crucial consequence of the activation of RA-SFs is
the expression and upregulation of different adhesion mol-
ecules that mediate the attachment of these cells to the
cartilage. Among the different adhesion molecules that
contribute to this process, b1 integrins appear to be
involved most significantly. The expression of b1 integrins
such as VLA-3, VLA-4 and VLA-5 on SFs has been
demonstrated in several studies [38,39]. Rinaldi et al also
demonstrated that antibodies against b1 integrin inhibited,
at least in part, the binding of RA-SFs to the extracellularmatrix [38]. Several integrins function as fibronectin recep-
tors, and therefore it has been suggested that the
fibronectin-rich environment of the RA cartilage surface
facilitates the adhesion of RA-SFs to the articular cartilage.
This notion was supported by data from Müller-Ladner et al
showing that CS-1, a spliced isoform of fibronectin, is
expressed highly in the RA synovium [40]. However, inte-
grins not only function as receptor molecules, but also
interact with several signaling pathways involved in the
pathogenesis of RA [41]. The expression of early cell cycle
genes such as c-fos and c-myc is specifically stimulated by
integrin-mediated cell adhesion. Gene expression driven by
the fos promoter shows strongly synergistic activation by
integrin-mediated cell adhesion [42,43]. These data con-
tribute to the understanding that the role of adhesion mole-
cules in RA is not restricted to the attachment of the
synovium to cartilage and bone, but involves complex regu-
latory functions including the recruitment of inflammatory
cells as well as the induction of MMP expression.
Role of RA-SFs in matrix degradation
It is now well understood that RA-SFs contribute signifi-
cantly to matrix degradation in RA through the expression
of matrix degrading enzymes such as MMPs [44] and
cathepsins [45] (Fig. 1). Interest has so far focused mainly
on the MMPs, and numerous reports have implicated
MMPs in rheumatoid joint destruction [46–50]. MMPs
have not only been found at elevated levels in synovial
fluid of RA patients [51], but in situ studies have revealed
strong expression of MMPs in the rheumatoid synovium
[50,52]. RA-SFs in the lining layer or at the sites of carti-
lage invasion have been identified as the major source of
MMPs. This pattern of distribution is similar to that for
proto-oncogenes and consistent with the notion that
proto-oncogenes are involved in the activation of MMP
genes. It was also shown that the expression levels of
some MMPs, such as MMP-13, correlate with elevated
levels of systemic inflammation markers [53]. The recently
described membrane type (MT)-MMPs have also been
found in activated RA-SFs of the lining layer [54]. This is
important because some of the known MT-MMPs not only
degrade extracellular matrix components, but also activate
other disease-relevant MMPs, such as MMP-2 and
MMP-13 [55]. In a recent study that compared the expres-
sion of MT-MMPs in RA, we found that MT1-MMP was
expressed most intensely in fibroblasts and macrophages,
and also in osteoclast-like cells at sites of bone resorption
[54]. From this study, we concluded that MT1-MMP and,
potentially, MT3-MMP contribute significantly to matrix
degradation in RA.
Cathepsins are another major group of proteases involved
in joint destruction [45]. The cysteine proteases cathepsin
B and cathepsin L, particularly, have been shown to be
activated by proto-oncogenes and upregulated in RA syn-
ovium at sites of cartilage invasion [56]. The finding that
transfection of fibroblasts with the ras proto-oncogene
leads to cellular transformation accompanied by the induc-
tion of cathepsin L [57] agrees with data demonstrating
the combined expression of ras and cathepsin L in
RA-SFs [58]. Several studies have also shown that pro-
inflammatory cytokines such as interleukin-1 (IL-1) and
TNFa can stimulate the production of cathepsins B and L
by SF-like cells [59,60]. Recent data have also implicated
cathepsin K in the matrix degradation by RA-SFs through
demonstrating the expression of cathepsin K in RA-SFs
and macrophages [61].
Interaction of RA-SFs with other cell types
Although it is now believed that the activation of RA-SFs is
caused by a set of events and can be maintained in the
absence of human inflammatory cytokines, pro-inflamma-
tory cytokines play a key role in the stimulation of RA-SFs
towards an aggressive behavior (Fig. 1). Among the
variety of cytokines and factors that have been shown to
enhance the activation and destructive potential of
RA-SFs, TNFa and IL-1 are of particular importance and
have been investigated in detail. This has led to the devel-
opment of novel therapeutic strategies targeting these
cytokines. The delivery of TNFa receptor fusion proteins
as well as novel monoclonal antibodies against TNFa has
provided the most promising results [62–64]. It was
demonstrated that administration of anti-TNFa antibodies
results not only in an improvement of inflammation, but
also in a reduction in the levels of MMPs in the sera of RA
patients. In this context, data from clinical trials indicate
that, in addition to reducing inflammation, such treatment
in combination with methotrexate may impact on the pro-
gression of radiological changes (RN Maini, personal com-
munication). However, the complexity of RA-SF activation
as already outlined raises the question of to what extent
inhibition of TNFa can influence the long-term outcome of
disease. This is because recent data indicate that TNFa
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Figure 1
Role of activated RA synovial fibroblasts in the pathogenesis of RA.
ODF, Osteoclast differentiating factor.may exert different effects on different subtypes of RA-SF
through a variation in the distribution of TNF receptor vari-
ants in the lining and sublining [65]. Data from animal
models of RA are more intriguing, suggesting that, despite
a certain overlap in the effect of TNFa and IL-1, there are
distinct differences with respect to inflammation and
matrix degradation [66]. While TNFa appears to have a
more pronounced effect on the extent of synovitis, IL-1
may have a greater impact on joint destruction. As demon-
strated by Bendele et al, the combination of methotrexate
and anti-IL-1 treatment resulted in a 97% reduction of
bone resorption [67].
The notion that RA-SFs not only react passively to pro-
inflammatory stimuli but also contribute actively to the
pathogenesis of RA is supported by recent findings
demonstrating a significant effect of RA-SFs on
macrophages and lymphocytes in the RA synovium. It
appears that RA-SFs play a significant role in the activa-
tion of macrophages in the lining and their differentiation
into multinucleated, osteoclast-like bone resorbing cells.
As cited in a review by Goldring and Gravallese published
in  Arthritis Research, recent studies have identified a
potent regulator of osteoclastogenesis, the osteoclast dif-
ferentiating factor in the RA synovium [68]. Shigeyama et
al interestingly demonstrated that RA-SFs produce large
amounts of osteoclast differentiating factor in vivo, which
correlates with the ability of these cells to induce osteo-
clastogenesis in peripheral blood monocytes in vitro [69].
Thus, RA-SFs contribute to the degradation of the extra-
cellular matrix not only directly through the release of
matrix degrading enzymes, but also indirectly through
effecting the differentiation and activation of osteoclasts
(Fig. 1). This close cooperation of macrophages and
fibroblasts in the RA synovium is documented further by
Hamann et al [70], who demonstrated that the coopera-
tion of synovial macrophages and fibroblasts is also medi-
ated through direct cell–cell interactions via ligation of
CD55 on RA-SFs with CD97 on macrophages. These
interactions appear to take place predominantly in the syn-
ovial lining that mediates the progressive destruction of
cartilage and bone.
Other data indicate that RA-SFs also influence the accu-
mulation and survival of lymphocytes in the RA synovium.
Franz et al demonstrated that RA-SFs constitute an impor-
tant source of IL-16, which has been demonstrated to be
chemoattractive for CD4-positive T cells [71]. IL-16 also
appears responsible—at least in part—for the anergic state
of T cells in the synovial tissue [72]. Interesting data con-
cerning the effects of RA-SFs have also emerged from a
study by Salmon et al demonstrating that isolated synovial
T cells rapidly undergo programmed cell death, whereas a
co-culture with SFs prevented apoptosis [73]. SFs
derived from patients with RA not only prevent T cells from
apoptosis: elegant studies by de Groot and co-workers
have shown that RA-SFs also prevent B lymphocytes from
programmed cell death [74].
Conclusion
On the basis of these data, it can be concluded that
RA-SFs contribute significantly to the survival of both B
and T lymphocytes in the diseased synovium, and thereby
maintain inflammation (Fig. 1). Based on the fact that
RA-SFs are pivotal players in the pathogenesis of joint
destruction, we have transferred specific genes to these
cells [8,9,75] to explore the distinct pathways of synovial
cell activation [76,77].
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